ArticleFrontiers in pediatrics2025
Case Report: Two episodes of hyperinflammation in an infant consistent with multisystem inflammatory syndrome in children: recurrence or rather two different diseases?
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory disease that occurs after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report a 9-month-old male infant with two episodes of hyperinflammatory disease, each involving the coronary arteries, within a short period of time during the SARS-CoV-2 pandemic. Although both episodes met the official criteria for MIS-C, this case illustrates the difficulty in distinguishing MIS-C from its main differential diagnosis, Kawasaki disease (KD). Recurrence of postviral hyperinflammatory disease is rare. Compared with KD, the recurrence of MIS-C is even rarer, but clinicians should be aware of this possibility. Our case also emphasizes the need to follow up these patients closely and to detect sequelae regularly, especially cardiovascular sequelae, at an early stage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.